Godavari Drugs (BOM:530317) ROCE %: 8.93% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530317 Godavari Drugs Ltd BOM:530317
54 GF Score
Price ₹102.50
GF Value ₹72.37
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Godavari Drugs ROCE %?

Godavari Drugs BOM:530317 -0.49% 54 ROCE % is 8.93% as of Mar. 2026. GuruFocus rates BOM:530317 with a GF Score™ of 54/100 and a GF Value™ of ₹72.37 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Godavari Drugs's annualized ROCE % for the quarter that ended in Mar. 2026 was 8.93%.

Godavari Drugs  (BOM:530317) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Godavari Drugs ROCE % Related Terms

Godavari Drugs ROCE % Historical Data

* Premium members only.

The historical data trend for Godavari Drugs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Godavari Drugs ROCE % Chart

Godavari Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.65 17.07 21.32 16.88 9.76

Godavari Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.56 13.18 10.40 10.93 8.93
BOM:530317
54GF Score
Godavari Drugs Ltd BOM:530317
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Godavari Drugs ROCE % Calculation

Godavari Drugs's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=90.427/( ( (1430.764 - 730.904) + (2004.313 - 851.443) )/ 2 )
=90.427/( (699.86+1152.87)/ 2 )
=90.427/926.365
=9.76 %

Godavari Drugs's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=102.924/( ( (0 - 0) + (2004.313 - 851.443) )/ 1 )
=102.924/( ( 0 + 1152.87 )/ 1 )
=102.924/1152.87
=8.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.93% mean?
Godavari Drugs (BOM:530317) has a ROCE % of 8.93% as of Mar. 2026.
Is Godavari Drugs' ROCE % too high?
Godavari Drugs' current ROCE % is 8.93%. The Drug Manufacturers industry median ROCE % is 6.94. Godavari Drugs' value of 8.93% is 28.8% above this industry median. Overall, Godavari Drugs has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' ROCE % compare to ZTS?
Godavari Drugs' ROCE % of 8.93% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 6.94. Godavari Drugs' value of 8.93% is 28.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 6.94, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Godavari Drugs's current ROCE % of 8.93% is 28.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 6.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Godavari Drugs's current ROCE % is 8.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹72.37, compared to a current price of ₹102.50 — trading 41.6% above its estimated fair value. The current ROCE % is 8.93% and 28.8% above the Drug Manufacturers industry median of 6.94. Godavari Drugs' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current ROCE % is 8.93% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Godavari Drugs (BOM:530317) Overvalued in 2026?

Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued. The current stock price of ₹102.50 is trading 41.6% above its estimated GF Value™ of ₹72.37. GuruFocus considers Godavari Drugs to be Significantly Overvalued.

Key valuation signals for BOM:530317:

  • ROCE %: 8.93%
  • GF Value™: ₹72.37 vs. price of ₹102.50 (41.6% above fair value)
  • GF Score™: 54/100 with 5 warning signs
  • Industry Position: 28.8% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Godavari Drugs Business Description

Address Sardar Patel Road, 1-8-303/34, Mayfair, 1st Floor, Secunderabad, TG, IND, 500 003
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
54GF Score

Get the complete analysis for BOM:530317

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹102.50
Price
₹72.37
GF Value